Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Stopped Due to study design (and toxicity), this trial closed to accrual prior to opening the phase II portion.
Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
Interventions
- DRUG: dexamethasone
- DRUG: sorafenib tosylate
- DRUG: Lenalidomide
Sponsor
Mayo Clinic
Collaborators